1. Introduction
===============

Breast cancer (BC) is one of the most frequently diagnosed gynecological cancers,^\[[@R1],[@R2]\]^ which is the second leading cause of cancer mortality.^\[[@R3],[@R4]\]^ It is reported that about 90% to 95% patients are diagnosed at early stage and 20% to 30% of them have metastatic.^\[[@R5]\]^ Bone metastatic (BM) is the most frequent metastases in patients with BC,^\[[@R6],[@R7]\]^ with \>75% of stage IV BC develop to BM, which is incurable for these patients.^\[[@R8],[@R9]\]^ Thus, it is very to treat BC at early stage. Although surgery is a mostly utilized management for patients with BC, there are still some patients suffering from BM after surgery.^\[[@R10]\]^ It is very important to detect BM in patients after breast cancer surgery (BCS).

Radionuclide is reported to diagnose BM after BCS.^\[[@R11]\]^ Despite a variety of studies utilized to detect BM after BCS, it remains uncertain whether radionuclide is accurate in diagnosis for BM after BCS.^\[[@R12]--[@R27]\]^ We therefore will perform a rigorous systematic review to comprehensively compare the accuracy of radionuclide with x-ray, or computed tomography, or magnetic resonance.

2. Methods
==========

2.1. Study registration
-----------------------

This study protocol was registered at CRD42020187646. It is reported according to the guidelines of the Preferred Reporting Items for Systematic Reviews and Meta-Analysis Protocol statement.^\[[@R28],[@R29]\]^

2.2. Eligibility criteria for study selection
---------------------------------------------

Studies will be eligible for inclusion if they are case-control studies (CCSs) on radionuclide in detection of BM after BCS; included patients who were diagnosed as breast cancer; compared BM with x-ray, computed tomography, magnetic resonance, regardless age, race, and severity of breast cancers; and reported outcomes of sensitivity, specificity, false negative rate, false positive rate, likelihood ratio, misdiagnosis rate, and diagnostic odds ratio.

We will exclude studies of animal studies, review, case report, case series, and non-clinical studies; and studies that did not focus on the radionuclide in detection of BM after BCS.

2.3. Strategy of literature retrievals
--------------------------------------

A systematic and comprehensive search of electronic databases (Cochrane Library, MEDLINE, EMBASE, Web of Science, CBM, and CNKI) will be performed until June 1, 2020. We will consider all eligible studies on the diagnosis of radionuclide in BM after BCS. The detailed search strategy is available for Cochrane Library in Table [1](#T1){ref-type="table"}. We will create similar search strategies for other electronic databases. Besides the electronic databases, this study will also search grey literature, such as conference proceedings, websites of clinical trial registry, and reference lists of relevant studies.
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2.4. Study selection
--------------------

Two independent authors will examine titles/abstracts of all searched records, and will eliminate irrelevant studies. We will carefully check full-text of all potential studies to determine whether such studies meet all eligible criteria. The results of study selection will be shown in a flow chart. Any disagreement will be solved by consultation or discussion with a third author.

2.5. Data extraction and management
-----------------------------------

Two independent authors will extract data from included CCSs using a priori designed form. It comprises of study characteristics (e.g., study name, source date, and country), participant demographics and characteristics (e.g., age, diagnostic criteria, and sample size), details of index and reference tests, outcomes, results, and findings. Any doubt between 2 authors will be interpreted by a third author through discussion. If missing or insufficient data is identified, we will contact original authors to request it. If it is not successful, we will analyze available data.

2.6. Study quality assessment
-----------------------------

We will appraise study quality using Quality Assessment of Diagnostic Accuracy Studies tool.^\[[@R30]\]^ Two authors will independently perform it. If there are conflicts regarding study quality evaluation, we will resolve them through discussion.

2.7. Measurements of treatment effect
-------------------------------------

Continuous data will be estimated by weighted mean difference or standardized mean difference and 95% confidence intervals (CIs); and dichotomous data will be estimated by risk ratio and 95% CIs.

2.8. Statistical analysis
-------------------------

Statistical analysis of this study will be completed using RevMan 5.3 software (London, UK). *I*^2^ test will be utilized to check statistical heterogeneity among included studies. *I*^2^ ≤ 50% denotes acceptable heterogeneity, and a fixed-effects model will be applied. If possible, we will also perform meta-analysis based on the sufficient similarity in study characteristics, patient demographic, and outcomes. *I*^2^ \> 50% means significant heterogeneity, and a random-effects model will be placed. We will carry out subgroup analysis to explore sources of heterogeneity in accordance with different study information, patient characteristics, and study quality.

In addition, we will perform a sensitivity analysis to assess the impact of uncertain parameters on primary findings, and to check its stability and robustness by excluding low quality studies. We will also conduct funnel plot^\[[@R31]\]^ and Egger regression test^\[[@R32]\]^ to identify reporting bias if 10 eligible studies are available.

3. Discussion
=============

BC is a rising major gynecological disease around the world.^\[[@R1],[@R2]\]^ Although a range of studies reported the accuracy of radionuclide in diagnosis of BM in patients after BCS,^\[[@R12]--[@R27]\]^ there is still limited evidence-based medicine evidence to support this point. Thus, this systematic review will critically investigate the accuracy of radionuclide in diagnosis of BM after BCS. The results of this study may yield evidence to help judge whether or not radionuclide is accurate in diagnosis of BM after BCS. Its findings may benefit clinical practice and patients, as well as associated researchers.

4. Ethics and dissemination
===========================

This study does not need ethic approval, because we will not collect individual patient data. The results of this study will be published on a peer-reviewed journal.
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